Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

Rhea-AI Summary

Clene Inc. (Nasdaq: CLNN) has announced its participation in significant events, including Roth's 35^th Annual Healthcare Conference from March 12^th-14^th and Renmark Financial's Virtual Non-Deal Roadshow Series on March 7^th and 22^nd. At the Roth Conference, Clene will present on March 13 at 3:30 p.m. EDT, accessible via a webcast link. Additionally, the Renmark events will feature a live Q&A with CEO Rob Etherington and CFO Morgan Brown. Interested individuals can register for both events through provided links. Clene aims to advance treatments for neurodegenerative diseases, highlighting their innovative work in this domain.

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will participate in Roth’s 35^th Annual Healthcare Conference set for March 12^th-14^th and in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on March 7^th and 22^nd.

EVENT DETAILS:

Roth 35^th Annual Healthcare Conference, March 12-14

Presentation/Fireside Chat Time: March 13 starting at 3:30 p.m. E.D.T
Webcast link: https://wsw.com/webcast/roth46/clnn/1826765

The webcast of this presentation will be posted to the Investors section of the Company’s website located at www.invest.clene.com.  

Renmark Virtual Non-Deal Roadshow Series

Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will deliver the latest investor presentation followed by a live Q&A session. Individuals can register by using the link below.

March 7 – 4 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-07-130000

March 22 – 2 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-22-130000

Registration for the Renmark events may be limited but access to the replays will be posted to the Investors section of the Company’s website within a few days of the events. To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

Contacts:

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

FAQ

What events will Clene Inc. (CLNN) participate in March 2023?

Clene Inc. will participate in Roth's 35^th Annual Healthcare Conference from March 12^th-14^th and Renmark Financial's Virtual Non-Deal Roadshow Series on March 7^th and 22^nd.

When is Clene's presentation at the Roth Conference?

Clene's presentation at the Roth Conference will take place on March 13, 2023, starting at 3:30 p.m. EDT.

How can I access the webcast of Clene's presentation?

The webcast of Clene's presentation will be available via a link shared in the press release and posted on their Investors section of the website.

Who will present at the Renmark Financial events for Clene (CLNN)?

Rob Etherington, CEO, and Morgan Brown, CFO, will present at the Renmark Financial events with a live Q&A session.

What is the focus of Clene Inc. (CLNN) as a company?

Clene is focused on revolutionizing the treatment of neurodegenerative diseases, targeting energetic failure, a common underlying cause.